Surrozen, Inc./DE Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Surrozen, Inc./DE (SRZN) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 21.97 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- Surrozen, Inc./DE antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 22.18M shares, a 4.85% increase year-over-year.
- Surrozen, Inc./DE antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 21.16M shares, a 2716.91% increase year-over-year.
- Surrozen, Inc./DE antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 751.00K shares, a 88.00% decline year-over-year.
- Surrozen, Inc./DE antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 6.26M shares, a 58089.94% increase year-over-year.
- Surrozen, Inc./DE antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 21.09M shares, a 73.63% increase from fiscal 2024.
- Surrozen, Inc./DE antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 12.14M shares, a 1519799.87% increase from fiscal 2023.
- Surrozen, Inc./DE antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 799.00 shares, a 20.69% increase from fiscal 2022.
- Surrozen, Inc./DE antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 662.00 shares, a 99.99% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 21.97M shares 10-Q · filed 2026-08-06 | |||||||
| 2026-03-31 | 22.18M shares 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | 21.09M shares 10-K · filed 2026-03-23 | |||||||
| 2025-09-30 | 21.50M shares 10-Q · filed 2025-11-07 | |||||||
| 2025-06-30 | 21.48M shares 10-Q · filed 2026-08-06 | |||||||
| 2025-03-31 | 21.16M shares 10-Q · filed 2026-05-06 | 8.40M shares 10-Q · filed 2025-05-09 | ||||||
| 2024-12-31 | 12.14M shares 10-K · filed 2026-03-23 | 12.14K shares 10-K · filed 2025-03-31 | ||||||
| 2024-09-30 | 12.16M shares 10-Q · filed 2025-11-07 | |||||||
| 2024-06-30 | 17.73M shares 10-Q · filed 2025-08-08 | |||||||
| 2024-03-31 | 751.00K shares 10-Q · filed 2025-05-09 | 6.26M shares 10-Q · filed 2024-05-08 | ||||||
| 2023-12-31 | 799.00 shares 10-K · filed 2025-03-31 | |||||||
| 2023-09-30 | 806.00K shares 10-Q · filed 2024-11-06 | 12.07K shares 10-Q · filed 2023-11-08 | ||||||
| 2023-06-30 | 6.25M shares 10-Q · filed 2024-08-12 | 10.99K shares 10-Q · filed 2023-08-09 | ||||||
| 2023-03-31 | 6.26M shares 10-Q · filed 2024-05-08 | 11.14K shares 10-Q · filed 2023-05-10 | ||||||
| 2022-12-31 | 662.00 shares 10-K · filed 2024-04-10 | 9.93M shares 10-K · filed 2023-03-31 | ||||||
| 2022-09-30 | 11.18K shares 10-Q · filed 2023-11-08 | 11.18M shares 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | 10.89K shares 10-Q · filed 2023-08-09 | 10.89M shares 10-Q · filed 2022-08-11 | ||||||
| 2022-03-31 | 10.75K shares 10-Q · filed 2023-05-10 | 5.34M shares 10-Q · filed 2022-05-11 | ||||||
| 2021-12-31 | 9.25M shares 10-K · filed 2023-03-31 | 9.25M shares 10-K · filed 2022-03-28 | ||||||
| 2021-09-30 | 9.20M shares 10-Q · filed 2022-11-14 | 9.20M shares 10-Q · filed 2021-11-15 | ||||||
| 2021-06-30 | 1.78M shares 10-Q · filed 2022-08-11 | |||||||
| 2021-03-31 | 1.77M shares 10-Q · filed 2022-05-11 | |||||||
| 2020-12-31 | 1.22M shares 10-K · filed 2022-03-28 | |||||||
| 2020-09-30 | 1.05M shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |